Human Genome Epidemiology Literature Finder
|
Records 1 - 12 (of 12 Records) |
| Query Trace: Disease and HSD3B1[original query] |
|---|
| Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 2007 Aug 70 (2): 374-9. Park Jong Y, Tanner Jean-Paul, Sellers Thomas A, Huang Yifan, Stevens Colleen K, Dossett Nicole, Shankar Ravi A, Zachariah Babu, Heysek Randy, Pow-Sang Jul |
| Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007 May 16 (5): 969-78. Cunningham Julie M, Hebbring Scott J, McDonnell Shannon K, Cicek Mine S, Christensen G Bryce, Wang Liang, Jacobsen Steven J, Cerhan James R, Blute Michael L, Schaid Daniel J, Thibodeau Stephen |
| Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010 Jan 19 (1): 1. Setlur Sunita R, Chen Chen X, Hossain Ruhella R, Ha Jung Sook, Van Doren Vanessa E, Stenzel Birgit, Steiner Eberhard, Oldridge Derek, Kitabayashi Naoki, Banerjee Samprit, Chen Jin Yun, Schäfer Georg, Horninger Wolfgang, Lee Charles, Rubin Mark A, Klocker Helmut, Demichelis Frances |
| Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Feb 19 (3): 699-709. Lévesque Éric, Huang Shu-Pin, Audet-Walsh Étienne, Lacombe Louis, Bao Bo-Ying, Fradet Yves, Laverdière Isabelle, Rouleau Mélanie, Huang Chao-Yuan, Yu Chia-Cheng, Caron Patrick, Guillemette Chant |
| HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer. Nature reviews. Urology 2017 12 15 (3): 191-196. Hettel Daniel, Sharifi Ni |
| Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer. JAMA oncology 2017 Oct . Hearn Jason W D, Xie Wanling, Nakabayashi Mari, Almassi Nima, Reichard Chad A, Pomerantz Mark, Kantoff Philip W, Sharifi Ni |
| HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer. JAMA oncology 2017 10 4 (4): 554-557. Almassi Nima, Reichard Chad, Li Jianbo, Russell Carly, Perry Jaselle, Ryan Charles J, Friedlander Terence, Sharifi Ni |
| Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT. Cancer biology & therapy 2020 Aug 1-3. Handy Whitney F, Schmidt Keith T, Price Douglas K, Figg William |
| Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. Annals of oncology : official journal of the European Society for Medical Oncology 2020 5 31 (9): 1178-1185. Lu C, Terbuch A, Dolling D, Yu J, Wang H, Chen Y, Fountain J, Bertan C, Sharp A, Carreira S, Isaacs W B, Antonarakis E S, De Bono J S, Luo |
| HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA oncology 2020 2 6 (4): e196496. Hearn Jason W D, Sweeney Christopher J, Almassi Nima, Reichard Chad A, Reddy Chandana A, Li Hong, Hobbs Brian, Jarrard David F, Chen Yu-Hui, Dreicer Robert, Garcia Jorge A, Carducci Michael A, DiPaola Robert S, Sharifi Ni |
| Prostate Cancer Mortality Associated with Aggregate Polymorphisms in Androgen-Regulating Genes: The Atherosclerosis Risk in the Communities (ARIC) Study. Cancers 2021 4 13 (8): . Prizment Anna E, McSweeney Sean, Pankratz Nathan, Joshu Corinne E, Hwang Justin H, Platz Elizabeth A, Ryan Charles |
| A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 11 169 115890. Stefan A J Buck, Marinda Meertens, Frederiek M F van Ooijen, Esther Oomen-de Hoop, Evert de Jonge, Marieke J H Coenen, Andries M Bergman, Stijn L W Koolen, Ronald de Wit, Alwin D R Huitema, Ron H N van Schaik, Ron H J Mathijss |
- Page last reviewed:Feb 1, 2024
- Content source: